Profile data is unavailable for this security.
About the company
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
- Revenue in USD (TTM)610.83m
- Net income in USD45.70m
- Incorporated1959
- Employees1.55k
- LocationTaro Pharmaceutical Industries Ltd14 Hakitor Street,PO Box 10347HAIFA 2624761IsraelISR
- Phone+972 48475700
- Fax+972 48727165
- Websitehttps://www.taro.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.44bn | 297.00 | 238.62 | 3.33 | 132.79 | 4.78 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.49bn | 174.00 | -- | 5.03 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Xencor Inc | 168.34m | -126.09m | 1.49bn | 280.00 | -- | 2.21 | -- | 8.88 | -2.10 | -2.10 | 2.79 | 10.96 | 0.1872 | -- | 8.36 | 601,207.10 | -14.04 | -3.70 | -15.30 | -4.12 | -- | -- | -75.00 | -15.92 | -- | -- | 0.0304 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.51bn | 124.00 | -- | 2.27 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Protagonist Therapeutics Inc | 60.00m | -78.96m | 1.51bn | 112.00 | -- | 4.42 | -- | 25.21 | -1.47 | -1.47 | 1.06 | 5.83 | 0.1981 | -- | 11.56 | 535,714.30 | -26.06 | -35.90 | -28.53 | -41.36 | -- | -- | -131.59 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Akero Therapeutics Inc | 0.00 | -151.76m | 1.52bn | 55.00 | -- | 2.29 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
| Dynavax Technologies Corp | 232.28m | -6.39m | 1.54bn | 408.00 | -- | 2.45 | -- | 6.63 | -0.0733 | -0.0733 | 1.65 | 4.80 | 0.2343 | 0.89 | 2.50 | 569,323.50 | -0.6444 | 4.16 | -0.7216 | 5.71 | 78.40 | 64.83 | -2.75 | 9.19 | 12.96 | -- | 0.2636 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Neumora Therapeutics Inc | 0.00 | -235.93m | 1.56bn | 124.00 | -- | 3.32 | -- | -- | -2.33 | -2.33 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Taro Pharmaceutical Industries Ltd | 610.83m | 45.70m | 1.59bn | 1.55k | 34.89 | 0.8962 | 20.08 | 2.61 | 1.22 | 1.22 | 16.25 | 47.33 | 0.2854 | 1.45 | 2.76 | 393,068.20 | 2.14 | 1.85 | 2.59 | 2.21 | 48.02 | 56.82 | 7.48 | 6.99 | 3.03 | -- | 0.00 | 0.00 | 2.07 | -2.85 | -56.33 | -34.53 | -7.64 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.60bn | 1.60k | -- | 0.4563 | -- | 2.15 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| ADMA Biologics Inc | 258.22m | -28.24m | 1.60bn | 624.00 | -- | 11.55 | -- | 6.20 | -0.1263 | -0.1263 | 1.14 | 0.5981 | 0.7621 | 1.01 | 12.03 | 413,806.10 | -8.33 | -24.80 | -9.60 | -28.00 | 34.44 | 17.02 | -10.94 | -51.31 | 1.69 | 0.924 | 0.4913 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Kura Oncology Inc | 0.00 | -168.09m | 1.61bn | 142.00 | -- | 3.18 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
| Soleno Therapeutics Inc | 0.00 | -38.99m | 1.62bn | 33.00 | -- | 9.41 | -- | -- | -2.97 | -2.97 | 0.00 | 4.97 | 0.00 | -- | -- | 0.00 | -37.64 | -53.90 | -41.40 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Novocure Ltd | 525.66m | -192.74m | 1.67bn | 1.45k | -- | 4.65 | -- | 3.18 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Supernus Pharmaceuticals Inc | 607.52m | 1.32m | 1.71bn | 652.00 | 1,228.80 | 1.85 | 19.86 | 2.82 | -0.0152 | -0.0152 | 10.71 | 16.84 | 0.4077 | 0.9918 | 3.92 | 931,780.70 | 0.0883 | 4.95 | 0.1315 | 6.41 | 86.21 | 88.61 | 0.2166 | 12.84 | 1.43 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
Data as of May 08 2024. Currency figures normalised to Taro Pharmaceutical Industries Ltd's reporting currency: US Dollar USD
10.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Krensavage Asset Management LLCas of 31 Dec 2023 | 646.45k | 1.72% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 579.40k | 1.54% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 555.09k | 1.48% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 545.68k | 1.45% |
| Brandes Investment Partners LPas of 31 Dec 2023 | 475.74k | 1.27% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 307.23k | 0.82% |
| Eversept Partners LPas of 31 Dec 2023 | 255.99k | 0.68% |
| Invesco Capital Management LLCas of 31 Dec 2023 | 235.86k | 0.63% |
| Murchinson Ltd.as of 31 Dec 2023 | 167.78k | 0.45% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 163.69k | 0.44% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
